Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis

Vélez, Iván Darío; Gilchrist, Katherine; Miceli, Sofia; Ramírez-Pineda, José R.; Ashman, Jill A.; Alves, Fabiana; Coler, Rhea N.; Bogatzki, Lisa Y.; Kahn, Stuart J.; Beckmann, Anna Marie; Cowgill, Karen D.; Reed, Steven G.; Piazza, Franco M.

doi:10.1016/j.vaccine.2009.10.045

Cited by 73 publications

(61 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[5][6][7][8][9][10][11][12][13][14] [15][16][17][18][19] Nevertheless, the main factor that has influenced this outbreak is the high number of military members who are entering the forest areas because of the armed conflict in the country and in the fight against drugs; therefore, they are the population group with the highest incidence of the disease. 20 The soldiers enter the jungle areas accompanied by dogs specially trained to detect landmines or illicit crops. This study aimed to identify and characterize the presence of CL in dogs belonging to the Colombian Army personnel who are monitoring the jungle areas of Colombia where no previous studies have been conducted.…”

Section: Introductionmentioning

confidence: 99%

An Epidemic Outbreak of Canine Cutaneous Leishmaniasis in Colombia Caused by Leishmania braziliensis and Leishmania panamensis

Vélez¹,

Carrillo²,

López³

et al. 2012

The American Journal of Tropical Medicine and Hygiene

Self Cite

View full text Add to dashboard Cite

Abstract. The largest recorded outbreak of cutaneous leishmaniasis in Colombia's history occurred during [2005][2006][2007][2008][2009] in soldiers of the Colombian Army, with~40,000 cases. This outbreak was caused by the influx of military personnel into the jungle with the mission of combat illicit crops and the guerrilla. The soldiers remain for long periods within the rainforest and are exposed to the bite of infected sand flies. During the military activities, soldiers work with dogs specially trained to detect landmines, and therefore, dogs are also exposed to the infected sand flies and show high incidence of cutaneous leishmaniasis (CL). This work describes an epidemic outbreak of canine CL caused by Leishmania braziliensis and Leishmania panamensis in Colombia, South America. The clinical features of the disease and the response to treatment with pentavalent antimonials observed in 72 guard dogs from the Colombian Army are described. A program for prevention and control of canine CL is also discussed.

show abstract

Section: Introductionmentioning

confidence: 99%

An Epidemic Outbreak of Canine Cutaneous Leishmaniasis in Colombia Caused by Leishmania braziliensis and Leishmania panamensis

Vélez¹,

Carrillo²,

López³

et al. 2012

The American Journal of Tropical Medicine and Hygiene

Self Cite

View full text Add to dashboard Cite

show abstract

“…Leish111f protects mice, hamsters, and rhesus macaques when appropriately formulated with adjuvant, and LEISH-F1ϩ monophosphoryl lipid A (MPL)-SE was the first defined Leishmania vaccine to enter clinical trials, where it demonstrated an excellent safety profile and induced antigen-specific responses (26)(27)(28)(29). A second, distinct E. coli-derived fusion, LEISH-F3, that combines two components that can protect in animal models of VL, nucleoside hydrolase (NH) and a sterol 24-c-methyltransferase (SMT), has also progressed through phase I clinical trial (30).…”

Section: Purified Recombinant Proteinsmentioning

confidence: 99%

Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis

Duthie

Reed

2017

Clin Vaccine Immunol

Self Cite

View full text Add to dashboard Cite

From experimental models and the analyses of patients, it is well documented that antigen-specific T cells are critical for protection against Leishmania infection. Effective vaccines require both targeting to the pathogen and an immune stimulant to induce maturation of appropriate immune responses. While a great number of antigens have been examined as vaccine candidates against various Leishmania species, few have advanced to human or canine clinical trials. With emphasis on antigen expression, in this minireview we discuss some of the vaccine platforms that are currently being explored for the development of Leishmania vaccines. It is clear that the vaccine platform of choice can have a significant impact upon the level of protection induced by particular antigens, and we provide and highlight some examples for which the vaccine system used has impacted the protective efficacy imparted.

show abstract

“…This is the LEISH-F1 + MPL-SE vaccine (previously called Leish-111F + MPL-SE) of Reed and co-workers [11], consisting of three recombinant Leishmania polyprotein LEISH-F1 antigens (TSALmSTI1-LeIF), together with the adjuvant monophosphoryl lipid and squalene in a stable emulsion (MPL-SE). After satisfactory completion of preclinical development and approval from the FDA, an initial phase 1 safety and immunogenicity trial was conducted in the USA followed by several studies initiated in Latin America [12] and recently in India (S. Reed, Personal communication, IDRI, Seattle, USA).…”

Section: Second-generation Vaccines In Clinical Developmentmentioning

confidence: 99%

Leishmaniasis vaccines: past, present and future

Modabber

2010

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis

Cited by 73 publications

References 52 publications

An Epidemic Outbreak of Canine Cutaneous Leishmaniasis in Colombia Caused by Leishmania braziliensis and Leishmania panamensis

An Epidemic Outbreak of Canine Cutaneous Leishmaniasis in Colombia Caused by Leishmania braziliensis and Leishmania panamensis

Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis

Leishmaniasis vaccines: past, present and future

Contact Info

Product

Resources

About